Matinas Biopharma (MTNB) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Matinas Biopharma is the larger company by market cap ($2.8 million vs $2.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTNB | XRTX |
|---|---|---|
| Share price | $2.87 | $1.41 |
| Market cap | $2.81M | $2.56M |
| 1-day change | +1.41% | -23.78% |
| Forward P/E | — | 1.76 |
| EPS (TTM) | $-17.80 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.95 | $7.05 |
| 52-week low | $2.27 | $1.36 |
| Distance from 52-week high | -90.09% | -80.00% |
| Average volume | 412.79K | 392.49K |
| Shares outstanding | 979.52K | 1.82M |
| Employees | 2 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
MTNB vs XRTX FAQ
Which is bigger, Matinas Biopharma or XORTX Therapeutics?
Matinas Biopharma (MTNB) is larger, with a market capitalization of $2.81M compared with $2.56M for XORTX Therapeutics (XRTX).
Are Matinas Biopharma and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.